154553-72-7

Upstream product

• 123-54-6 acetylacetone 
• 7144-20-9 2-Amino-4,6-dimethylnicotinamide 
• 116636-30-7 5,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one 
• 133240-06-9 5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine 
• 589-15-1 1-bromomethyl-4-bromobenzene 

Downstream Products

• 145004-88-2 4'-(2-Ethyl-5,7-dimethyl-imidazo[4,5-b]pyridin-3-ylmethyl)-biphenyl-2-sulfonic acid tert-butylamide 
• 154553-70-5 4'-(2-Ethyl-5,7-dimethyl-imidazo[4,5-b]pyridin-3-ylmethyl)-5-propyl-biphenyl-2-sulfonic acid tert-butylamide 
• 151467-35-5 5,7-dimethyl-2-ethyl-3-[[4-[2-(N-t-butylaminosulfonyl)-5-iso-butyl-3-thienyl]phenyl]methyl]-imidazo[4,5-b ]pyridine 
• 1197880-09-3 (E)-methyl 3-(4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl)acrylate 
• 1197880-08-2 (E)-3-(4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl)prop-2-en-1-ol 
• 1197879-16-5 (E)-2-ethyl-3-(4-(3-(4-isopropylpiperazin-1-yl)prop-1-en-1-yl)benzyl)-5,7-dimethyl-3H-imidazo[4,5-b]pyridine 
• 1197880-39-9 3-{4-[(E)-4-(tert-butyl-dimethyl-silanoxy)-but-1-enyl]-benzyl}-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine 
• 137421-61-5 4-[(5,7-Dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine-3-yl)methyl]benzeneamine 
• 169281-51-0 5-Ethyl-4'-(2-ethyl-5,7-dimethyl-imidazo[4,5-b]pyridin-3-ylmethyl)-biphenyl-2-sulfonic acid amide 
• 151467-40-2 3-[4-(2-ethyl-5,7-dimethyl-imidazo[4,5-b]pyridin-3-ylmethyl)-phenyl]-5-isobutyl-thiophene-2-sulfonic acid amide 

Relevant academic research and scientific papers

BIARYLMETHYL HETEROCYCLES

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis

GPR4, a G-protein coupled receptor, functions as a proton sensor being activated by extracellular acidic pH and has been implicated in playing a key role in acidosis associated with a variety of inflammatory conditions. An orally active GPR4 antagonist 39c was developed, starting from a high throughput screening hit 1. The compound shows potent cellular activity and is efficacious in animal models of angiogenesis, inflammation and pain.

IMIDAZO PYRIDINE DERIVATIVES

The invention relates to novel imidazopyridine derivatives and to their use in the treatment of diseases and disorders which may e.g. involve angiogenesis and/or pain, including autoimmune and inflammatory diseases.

Polymorphic forms of an angiotensin II antagonist

Polymorphic forms of the angiotensin II receptor antagonist, 3-[2''-(N-benzoyl)sulfonamidobiphenyl-4-yl]methyl-5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine and a method for the preparation of these crystal forms.

New approach to the imidazolutidine moiety of MK-996

A highly effective, regio-selective synthesis of imidazolutidine (1) is described starting from readily available malonamamidine hydrochloride and 2,4-pentanedione.